GLP-1 users push protein brands to rethink sweetness

Protein brands are running into a sweeter problem as GLP-1 drugs change how appetite, bitterness and aftertaste land. In IFF’s 2024 study, 85% of U.S. GLP-1 consumers said their food and beverage preferences changed after starting the medication, including shifts in sweetness, bitterness, fatty foods and mouthfeel.

That matters for bars, shakes and drinkable nutrition because sweeteners have long done three jobs at once: cover bitterness, support low-sugar claims and keep calories in check. GLP-1 users complicate all three. When portions shrink and appetite falls, the same sweetness level can feel louder, the finish can linger longer, and a product built for mass-market indulgence can start reading as too much.

Tate & Lyle’s May 2025 research, based on 500 active and former GLP-1 users across North America, points to a second audience that protein brands cannot ignore. Former users may still need satiety-supporting foods after medication, because hunger can return and food noise can come back. That puts protein, fiber and nutrient-dense formulations in a different role: not just weight management, but a bridge between smaller appetites and a more ordinary eating pattern.

The formulation brief across the ingredients business has started to reflect that shift. In 2026, the conversation is moving beyond sugar reduction alone toward clean sweetness, higher protein, fiber and nutrient density in smaller portions. Ingredion, Kerry, ADM and Cargill are all operating in that lane, because the winning formulas for GLP-1 users are unlikely to be the sweetest ones on shelf. They are more likely to be the ones that feel precise, with a clear flavor profile and a finish that does not overstay its welcome.

The catch is that the science is still lagging the market. There is little research on whether GLP-1-related taste changes affect sugar and artificial sweeteners differently, so brands are making choices about intensity, texture and aftertaste before the evidence is fully settled. For protein, that makes sweetener strategy a front-line product decision, not a back-of-house ingredient swap.